ACRO BIOMEDICAL CO., LTD.: total liabilities
Total liabilities for ACRO BIOMEDICAL CO., LTD. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ACRO BIOMEDICAL CO., LTD. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-09-30 to 2024-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2024-12-31 | 326,946 | USD | 2025-07-24 | 10-K · 0001640334-25-001300 |
| At date | 2023-12-31 | 315,473 | USD | 2025-07-24 | 10-K · 0001640334-25-001300 |
| At date | 2022-12-31 | 201,116 | USD | 2025-07-18 | 10-K · 0001640334-25-001245 |
| At date | 2021-12-31 | 117,370 | USD | 2023-07-21 | 10-K · 0001640334-23-001347 |
| At date | 2020-12-31 | 312,185 | USD | 2022-04-15 | 10-K · 0001640334-22-000809 |
| At date | 2019-12-31 | 133,887 | USD | 2021-04-02 | 10-K · 0001640334-21-000767 |
| At date | 2019-09-30 | 195,792 | USD | 2020-01-07 | 10-K · 0001640334-20-000007 |
| At date | 2018-09-30 | 240,675 | USD | 2020-01-07 | 10-K · 0001640334-20-000007 |
| At date | 2017-09-30 | 36,979 | USD | 2018-12-28 | 10-K · 0001640334-18-002423 |
| At date | 2016-09-30 | 17,326 | USD | 2018-01-16 | 10-K/A · 0001640334-18-000103 |
| At date | 2015-09-30 | 825 | USD | 2016-12-16 | 10-K · 0001640334-16-002238 |
Related financial histories
- ACRO BIOMEDICAL CO., LTD.: total assets
- ACRO BIOMEDICAL CO., LTD.: stockholders equity
- ACRO BIOMEDICAL CO., LTD.: cash and cash equivalents
- ACRO BIOMEDICAL CO., LTD.: net income or loss
- ACRO BIOMEDICAL CO., LTD.: operating cash flow
- ACRO BIOMEDICAL CO., LTD.: revenue
- ACRO BIOMEDICAL CO., LTD.: financing cash flow
- ACRO BIOMEDICAL CO., LTD.: retained earnings or deficit
- ACRO BIOMEDICAL CO., LTD.: diluted weighted-average shares
- ACRO BIOMEDICAL CO., LTD.: diluted earnings per share
- ACRO BIOMEDICAL CO., LTD.: income tax expense or benefit
- ACRO BIOMEDICAL CO., LTD.: share-based compensation expense
- ACRO BIOMEDICAL CO., LTD.: operating income or loss
- ACRO BIOMEDICAL CO., LTD.: current assets
- ACRO BIOMEDICAL CO., LTD.: interest expense
- ACRO BIOMEDICAL CO., LTD.: current liabilities
- ACRO BIOMEDICAL CO., LTD.: operating expenses
- ACRO BIOMEDICAL CO., LTD.: net inventory
- ACRO BIOMEDICAL CO., LTD.: gross profit
- ACRO BIOMEDICAL CO., LTD.: cost of revenue
- ACRO BIOMEDICAL CO., LTD.: selling, general and administrative expense
- ACRO BIOMEDICAL CO., LTD.: research and development expense
Inspect the source
- Entity
- ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
- Captured
- 2026-09-19T11:19:47.057Z
- SEC response SHA-256
b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))